Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study
Paolo Verdecchia, MD, FACC*,a,
Giancarlo Carini, MDa,
Antonio Circo, MDa,
Emilio Dovellini, MDa,
Ezio Giovannini, MDa,
Michele Lombardo, MDa,
Pasquale Solinas, MDa,
Marco Gorini, MDa,
Aldo Pietro Maggioni, MDa the MAVI Study Group
a ANMCO Research Center, Via La Marmora, 36 Firenze, Italy. Please see for MAVI Study Group participants

View larger version (22K):
[in a new window]
|
Figure 1 Distribution of antihypertensive regimens at entry and on follow-up. ACE = angiotension-converting enzyme.
|
|

View larger version (18K):
[in a new window]
|
Figure 2 Cumulative incidence (left) and crude rate (right) of cardiovascular (CV) events in the subjects with and without left ventricular (LV) hypertrophy at echocardiography. BSA = body surface area.
|
|
|